SHA: 600645

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas
CompanyDrug

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that its CD30 antibody‑drug conjugate (ADC) Adcetris (generic name: brentuximab vedotin for injection) has been officially approved by China's National Medical…

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo's ADC Wins Conditional Approval for HER2-Expressing Solid Tumors

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo’s ADC Wins Conditional Approval for HER2-Expressing Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment
CompanyDrug

Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment

Vcanbio's VUM02 Secures NMPA Approval and FDA ODD for Cirrhosis and aGvHD
CompanyDrug

Vcanbio’s VUM02 Secures NMPA Approval and FDA ODD for Cirrhosis and aGvHD

CompanyDrug

Vcanbio’s Stem Cell Therapy VUM02 Gets NMPA Approval for Systemic Sclerosis Clinical Trial

CompanyDeals

Ping An Good Doctor Partners with Vcanbio to Pioneer Cell Health Management Services in China

CompanyDrug

Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment

CompanyDrug

Vcanbio Receives NMPA Approval for Stem Cell Therapy VUM02 Clinical Trial

CompanyDrug

Vcanbio Receives Orphan Drug Designation for VUM02 in Idiopathic Pulmonary Fibrosis Treatment

CompanyDrug

Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment

Show More